Abstract
Urinary dysfunction (UD) is a common non-motor feature of Parkinson’s disease (PD), and might be secondary to neurodegeneration involving cortical and subcortical brain areas. The possible link between UD and cognitive deficits has never been examined in frontal cortex impairment, and is still not completely understood in PD. In the present study, 94 PD patients underwent a comprehensive motor, cognitive and non-motor assessment. It was shown that 55.3% of patients reported UD, of which 17% needed specific urological treatment. Patients who reported UD performed worse on global cognition (PANDA, p = .05), visuo-constructive functions (CERAD/praxis, p = .03; and Figure Test, p = .03), and instrumental activities of daily living functions (IADL, p = .03), than patients without UD. The group with UD medication performed worse on global cognition (PANDA, p = .02) and visuo-constructive functions (CERAD/praxis, p = .05; CERAD/praxis recall, p = .05) than the UD group without medication, independent of anticholinergic treatment effect. Our findings suggest an association between cognitive impairment and UD in PD independent from symptomatic treatment.
Similar content being viewed by others
References
Araki I, Kuno S (2000) Assessment of voiding dysfunction in Parkinson’s disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry 68:429–433
Araki I, Kitahara M, Oida T, Kuno S (2000) Voiding dysfunction and Parkinson’s disease: urodynamic abnormalities and urinary symptoms. J Urol 164:1640–1643
Blackett H, Walker R, Wood B (2009) Urinary dysfunction in Parkinson’s disease: a review. Parkinsonism Relat Disord 15:81–87. doi:10.1016/j.parkreldis.2007.10.016
Campos-Sousa RN, Quagliato E, da Silva BB, de Carvalho RM Jr, Ribeiro SC, de Carvalho DF (2003) Urinary symptoms in Parkinson’s disease: prevalence and associated factors. Arq Neuropsiquiatr 61:359–363
Crispo JA et al (2016) Associations between anticholinergic burden and adverse health outcomes in Parkinson disease. PLoS One 11:e0150621. doi:10.1371/journal.pone.0150621
Crook T, Larrabee G (1992) Normative data on a self-rating scale for evaluating memory in everyday life. Arch Clin Neuropsychol 7:41–51
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308–2314
de Groat WC, Griffiths D, Yoshimura N (2015) Neural control of the lower urinary tract. Compr Physiol 5:327–396. doi:10.1002/cphy.c130056
Dubois B, Burn D, Goetz C, Aarsland C, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lee AS, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow W, Poewe W, Sampaio C, Tolosa E, Emre M (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314–2324
Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D (2010) Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study. J Neurol Neurosurg Psychiatry 81:160–165. doi:10.1136/jnnp.2009.186239
Fahn S, Elton RL, Members of the UPDRS Development Committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease, vol 2. Macmillan Health care Information, Florham Park, NJ, pp 153–164
Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB (2015) New clinical subtypes of parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 72:863–873. doi:10.1001/jamaneurol.2015.0703
Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198
Fowler CJ, Griffiths DJ (2010) A decade of functional brain imaging applied to bladder control. Neurourol Urodyn 29:49–55. doi:10.1002/nau.20740
Graf C (2009) The Lawton instrumental activities of daily living (IADL) scale. Medsurg Nurs 18:315–316
Haerting C, et al (2000) Wechsler Gedächtnisstest-revidierte Fassung deutsche Adaptation der revidierten Fassung der Wechsler Memory scale. Huber, Bern, Switzerland
Hautzinger M, Bailer M, Worall H, Keller F (1995) Beck-Depressions-Inventar (BDI), vol 2. Huber, Bern
Kalbe E (2007) Sensitivity and specificity of the “Parkinson Neuropsychometric Dementia Assessment” (PANDA): Results of the GEPAD-Study. Aktuelle Neurologie 34:140–146
Kitta T, Chancellor MB, de Groat WC, Shinohara N, Yoshimura N (2016) Role of the anterior cingulate cortex in the control of micturition reflex in a rat model of Parkinson’s disease. J Urol 195:1613–1620. doi:10.1016/j.juro.2015.11.039
Leroi I, McDonald K, Pantula H, Harbishettar V (2012) Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J Geriatr Psychiatry Neurol 25:208–214. doi:10.1177/0891988712464823
Liepelt-Scarfone I (2007) Der Berliner-Apraxie-Test für ideomotorische und ideatorische Apraxie - Bestimmung der Itemkennwerte. Zeitschrift für Neuropsychologie 18(3):193–206
Liepelt-Scarfone I et al (2012) Cognitive profiles in Parkinson’s disease and their relation to dementia: A data-driven approach. Int J Alzheimers Dis 2012:910757. doi:10.1155/2012/910757
Liepelt-Scarfone I et al (2015) Autonomic dysfunction in subjects at high risk for Parkinson’s disease. J Neurol 262:2643–2652. doi:10.1007/s00415-015-7888-z
Litvan I et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord Off J Mov Disord Soc 27:349–356. doi:10.1002/mds.24893
Martinez-Martin P, Falup-Pecurariu C, Rodriguez-Blazquez C, Serrano-Duenas M, Carod Artal FJ, Rojo Abuin JM, Aarsland D (2011) Dementia associated with Parkinson’s disease: applying the Movement Disorder Society Task Force criteria. Parkinsonism Relat Disord 17:621–624. doi:10.1016/j.parkreldis.2011.05.017
Memory Clinic-NPZ (2005) The consortium to establish a registry of Alzheimer’s disease CERAD-plus. Basel Memory Clinic-NPZ, Basel
Oswald WD, Fleischmann UM (1999) Nurnberger-Alters-Inventar (NAI), vol 4. Hogrefe, Gottingen, Germany
Pilleri M, Koutsikos K, Antonini A (2013) Is there room for new non-dopaminergic treatments in Parkinson’s disease? J Neural Transm 120:349–352. doi:10.1007/s00702-012-0947-z
Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE (2008) The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 168:508–513. doi:10.1001/archinternmed.2007.106
Sakakibara R, Uchiyama T, Yamanishi T, Shirai K, Hattori T (2008) Bladder and bowel dysfunction in Parkinson’s disease. J Neural Transm 115:443–460. doi:10.1007/s00702-007-0855-9
Sakakibara R, Tateno F, Kishi M, Tsuyuzaki Y, Uchiyama T, Yamamoto T (2012) Pathophysiology of bladder dysfunction in Parkinson’s disease. Neurobiol Dis 46:565–571. doi:10.1016/j.nbd.2011.10.002
Sakakibara R et al (2013) Depression, anxiety and the bladder. Low Urin Tract Symptoms 5:109–120. doi:10.1111/luts.12018
Sakakibara R et al (2014) Bladder function of patients with Parkinson’s disease. Int J Urol 21:638–646. doi:10.1111/iju.12421
Smith M, Seth J, Batla A, Hofereiter J, Bhatia KP, Panicker JN (2016) Nocturia in patients with Parkinson's disease. Mov Disord Clinical Practice 3:168–172
Tateno F et al (2015) Lower urinary tract function in dementia with Lewy bodies (DLB). Mov Disord Off J Mov Disord Soc 30:411–415. doi:10.1002/mds.25985
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord Off J Mov Disord Soc 25:2649–2653. doi:10.1002/mds.23429
Toucha, L (2004) Turm von London – Deutsche Version TL-D. Hogrefe, Göttingen
Uchiyama T et al (2011) Urinary dysfunction in early and untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry 82:1382–1386. doi:10.1136/jnnp.2011.241075
Warrington EK, James M (1991) The visual object and space perception battery. Thames Valley Test Company, Bury St Edmunds
Wenning GK, Tison F, Seppi K, et al (2004) Development and validation of the unified multiple system atrophy rating scale. Mov Disord Off J Mov Disord Soc 19:1391–1402. doi:10.1002/mds.20255
Winge K, Fowler CJ (2006) Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord Off J Mov Disord Soc 21:737–745. doi:10.1002/mds.20867
Winge K, Nielsen KK (2012) Bladder dysfunction in advanced Parkinson’s disease. Neurourol Urodyn 31:1279–1283. doi:10.1002/nau.22237
Winge K, Werdelin LM, Nielsen KK, Stimpel H (2004) Effects of dopaminergic treatment on bladder function in Parkinson’s disease. Neurourol Urodyn 23:689–696. doi:10.1002/nau.20054
Winge K, Skau AM, Stimpel H, Nielsen KK, Werdelin L (2006) Prevalence of bladder dysfunction in Parkinsons disease. Neurourol Urodyn 25:116–122. doi:10.1002/nau.20193
Yamamoto T et al (2009) Questionnaire-based assessment of pelvic organ dysfunction in multiple system atrophy. Mov Disord 24(7):972–978. doi:10.1002/mds.22332
Zimmermann P, Fimm B (2002) A test battery for attentional performance (version 1.7). Psytests, Herzogenrath
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Funding
DPV Research Grant 2014/2015
Additional information
D. Berg and I. Liepelt-Scarfone contributed to this work equally.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Tkaczynska, Z., Pilotto, A., Becker, S. et al. Association between cognitive impairment and urinary dysfunction in Parkinson’s disease. J Neural Transm 124, 543–550 (2017). https://doi.org/10.1007/s00702-017-1690-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-017-1690-2